These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33290765)

  • 21. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.
    Yang Y; Li S; Wang Y; Zhao Y; Li Q
    Signal Transduct Target Ther; 2022 Sep; 7(1):329. PubMed ID: 36115852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.
    Lee CC; Shiao HY; Wang WC; Hsieh HP
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1333-48. PubMed ID: 24921970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer.
    Kuwano M; Sonoda K; Murakami Y; Watari K; Ono M
    Pharmacol Ther; 2016 May; 161():97-110. PubMed ID: 27000770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
    Levitzki A; Klein S
    Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11579-11586. PubMed ID: 31076554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small molecule tyrosine kinase inhibitors in glioblastoma.
    Kim G; Ko YT
    Arch Pharm Res; 2020 Apr; 43(4):385-394. PubMed ID: 32239429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired Resistance to Drugs Targeting Tyrosine Kinases.
    Rosenzweig SA
    Adv Cancer Res; 2018; 138():71-98. PubMed ID: 29551130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma.
    Nakada M; Kita D; Watanabe T; Hayashi Y; Hamada J
    Brain Tumor Pathol; 2014 Jul; 31(3):198-207. PubMed ID: 24399202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors.
    Moradpour Z; Barghi L
    J Pharm Pharm Sci; 2019; 22(1):37-48. PubMed ID: 30636671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
    Terada T; Noda S; Inui K
    Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.
    Tong CWS; Wu WKK; Loong HHF; Cho WCS; To KKW
    Cancer Lett; 2017 Oct; 405():100-110. PubMed ID: 28774798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
    Bixby D; Talpaz M
    Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress on treatment of MET signaling pathway in non-small cell lung cancer.
    Yu X; Yu S; Fan Y
    Int J Clin Oncol; 2020 Aug; 25(8):1450-1458. PubMed ID: 32440811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.